MU vs. KNSA
MU (Micron Technology, Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. MU operates in Semiconductors (Technology), while KNSA operates in Biotechnology (Healthcare). Over the past 5 years, MU returned 72.13%/yr vs 29.69%/yr for KNSA. At a 0.18 correlation, their price movements are largely independent.
Performance
MU vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MU achieves a 297.49% return, which is significantly higher than KNSA's 33.60% return.
MU
- 1D
- 8.70%
- 1M
- 51.00%
- YTD
- 297.49%
- 6M
- 326.79%
- 1Y
- 819.66%
- 3Y*
- 157.01%
- 5Y*
- 72.13%
- 10Y*
- 57.57%
KNSA
- 1D
- 1.66%
- 1M
- 3.51%
- YTD
- 33.60%
- 6M
- 27.60%
- 1Y
- 93.78%
- 3Y*
- 52.43%
- 5Y*
- 29.69%
- 10Y*
- —
MU vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
MU Micron Technology, Inc. | 297.49% | 240.24% | -0.96% | 71.93% | -45.93% | 24.21% | 39.79% | 69.49% | -47.09% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 33.60% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 14.89% |
Correlation
The correlation between MU and KNSA is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.12 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.18 |
Fundamentals
MU:
$1.29T
KNSA:
$4.54B
MU:
$21.26
KNSA:
$0.92
MU:
53.35
KNSA:
59.85
MU:
0.20
KNSA:
0.58
MU:
22.13
KNSA:
5.80
MU:
17.84
KNSA:
7.50
MU:
$58.12B
KNSA:
$754.05M
MU:
$33.96B
KNSA:
$294.06M
MU:
$25.99B
KNSA:
$101.06M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MU vs. KNSA — Risk / Return Rank
MU
KNSA
MU vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Micron Technology, Inc. (MU) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MU | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +9.56 | ||
| Sortino ratioReturn per unit of downside risk | +3.03 | ||
| Omega ratioGain probability vs. loss probability | 1.80 | 1.41 | +0.39 |
| Calmar ratioReturn relative to maximum drawdown | 27.79 | 4.63 | +23.16 |
| Martin ratioReturn relative to average drawdown | 105.40 | 16.35 | +89.05 |
Loading charts...
Drawdowns
MU vs. KNSA - Drawdown Comparison
The maximum MU drawdown since its inception was -98.25%, which is greater than KNSA's maximum drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for MU and KNSA.
Loading charts...
Drawdown Indicators
| MU | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.25% | -83.06% | -15.19% |
Max Drawdown (1Y)Largest decline over 1 year | -30.28% | -21.12% | -9.16% |
Max Drawdown (3Y)Largest decline over 3 years | -57.63% | -34.14% | -23.49% |
Max Drawdown (5Y)Largest decline over 5 years | -57.63% | -53.17% | -4.46% |
Max Drawdown (10Y)Largest decline over 10 years | -57.63% | — | — |
Current DrawdownCurrent decline from peak | 0.00% | -7.35% | +7.35% |
Average DrawdownAverage peak-to-trough decline | -58.14% | -40.60% | -17.54% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.97% | 5.97% | +2.00% |
Volatility
MU vs. KNSA - Volatility Comparison
Micron Technology, Inc. (MU) has a higher volatility of 33.27% compared to Kiniksa Pharmaceuticals, Ltd. (KNSA) at 10.40%. This indicates that MU's price experiences larger fluctuations and is considered to be riskier than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MU | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 33.27% | 10.40% | +22.87% |
Volatility (6M)Calculated over the trailing 6-month period | 58.61% | 34.02% | +24.59% |
Volatility (1Y)Calculated over the trailing 1-year period | 71.09% | 43.03% | +28.06% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 53.57% | 53.48% | +0.09% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 50.34% | 63.93% | -13.59% |
Dividends
MU vs. KNSA - Dividend Comparison
MU's dividend yield for the trailing twelve months is around 0.04%, while KNSA has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
KNSA Kiniksa Pharmaceuticals, Ltd. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MU Micron Technology, Inc. | 0.04% | 0.16% | 0.55% | 0.54% | 0.89% | 0.21% |
Financials
MU vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between Micron Technology, Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
MU vs. KNSA - Profitability Comparison
MU - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Micron Technology, Inc. reported a gross profit of 17.75B and revenue of 23.86B. Therefore, the gross margin over that period was 74.4%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.
MU - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Micron Technology, Inc. reported an operating income of 16.13B and revenue of 23.86B, resulting in an operating margin of 67.6%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.
MU - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Micron Technology, Inc. reported a net income of 13.79B and revenue of 23.86B, resulting in a net margin of 57.8%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.
Frequently Asked Questions
MU and KNSA have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MU has higher volatility (33.27%) compared to KNSA (10.40%). In terms of maximum drawdown, MU dropped -98.25% vs KNSA's -83.06%.
MU currently has the higher Sharpe Ratio (11.84 vs 2.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MU and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer